Morgan Stanley Upgrades ResMed (RMD) to Overweight
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Needham Starts NeoVolta (NEOV) at Buy
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
ResMed (RMD) PT Bumped to $66 at Needham & Company Posts Q4
July 31, 2015 8:02 AM EDTNeedham & Company analyst Mike Matson reiterated a Buy rating and raised his price target on ResMed (NYSE: RMD) to $66.00 (from $65.00) following solid Q4 results driven by flow generator product cycle.
Matson commented, "RMD's revenue and EPS beat consensus as its revenue... More
Deutsche Bank Downgrades ResMed (RMD) to Sell
July 31, 2015 7:32 AM EDTDeutsche Bank downgraded ResMed (NYSE: RMD) from Hold to Sell with a price target of $53.00 (from $61.00). The change follows Q4 results. Analyst David Low noted strong sales offset by GM weakness.
"After the incredible success of ResMeds AirSense range we are wary FY16... More
ResMed (RMD) Tops Q4 EPS by 3c, Revenue Beats
July 30, 2015 4:52 PM EDTResMed (NYSE: RMD) reported Q4 EPS of $0.68, $0.03 better than the analyst estimate of $0.65. Revenue for the quarter came in at $453.1 million versus the consensus estimate of $436.73 million.
For earnings history and earnings-related data on ResMed (RMD) click here.
... More